Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice
Figure 1
Chronic dual PPARα/δ agonist, elafibranor, treatment improved severity of adiposity in HFD mice with steatohepatitis. (a) Treatment protocol; (b) growth curves of HFD or NC mice: elafibranor decreased the trend of increased body weight, which can be abolished by concomitant SIRT1 inhibitor (EX527) treatment. Food and water consumption was estimated by daily observation at the time of feeding, and body weight was recorded every 2 weeks. (c) Representative image and bar graphs of H-E stain for hepatic steatosis: elafibranor decreased the severity of steatohepatitis; (d-e) whole body fat and lean mass of mice: elafibranor significantly reduced the fat mass of HFD mice. p<0.05,0.01 versus NC-group. ,p<0.05, 0.01 versus HFD-group; p<0.05 versus HFD-elaf group.